A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice
eLife · 19.04.2024 · 13
DOI: 10.7554/elife.89157 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 19.04.2024. Verfasst von Moagi Tube Shaku und 6 weiteren Autor:innen. Beteiligte Einrichtung: DST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Serv…. Hauptthemen laut MEDLINE: Peptidoglycan, BCG Vaccine, Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Mechanisms by which Mycobacterium tuberculosis (Mtb) evades pathogen recognition receptor activation during infection may offer insights for the development of improved tuberculosis (TB) vaccines. Whilst Mtb elicits NOD-2 activation through host recognition of its peptidoglycan-derived muramyl dipeptide (MDP), it masks the endogenous NOD-1 ligand through amidation of glutamate at the second position in peptidoglycan side-chains. As the current BCG vaccine is derived from pathogenic mycobacteria, a similar situation prevails. To alleviate this masking ability and to potentially improve efficacy of the BCG vaccine, we used CRISPRi to inhibit expression of the essential enzyme pair, MurT-GatD, implicated in amidation of peptidoglycan side-chains. We demonstrate that depletion of these enzymes results in reduced growth, cell wall defects, increased susceptibility to antibiotics, altered spatial localization of new peptidoglycan and increased NOD-1 expression in macrophages. In cell culture experiments, training of a human monocyte cell line with this recombinant BCG yielded improved control of Mtb growth. In the murine model of TB infection, we demonstrate that depletion of MurT-GatD in BCG, which is expected to unmask the D-glutamate diaminopimelate (iE-DAP) NOD-1 ligand, yields superior prevention of TB disease compared to the standard BCG vaccine. In vitro and in vivo experiments in this study demonstrate the feasibility of gene regulation platforms such as CRISPRi to alter antigen presentation in BCG in a bespoke manner that tunes immunity towards more effective protection against TB disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa.
- Center for Tuberculosis Research, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, United States.
- Department of Chemistry, University of Virginia, Charlottesville, United States.
ORCID-Profile: Moagi Tube Shaku, Peter K Um, William R Bishai, Bavesh D Kana
Förderung
- NIAID NIH HHS
- NIH HHS
- Howard Hughes Medical Institute
- South African Medical Research Council
- National Research Foundation
- National Institutes of Health
Zitieren
APA
Shaku, M. T., Um, P. K., Ocius, K. L., Apostolos, A. J., Pires, M. M., Bishai, W. R., & Kana, B. D. (2024). A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice. eLife, 13. https://doi.org/10.7554/elife.89157
Vancouver
Shaku MT, Um PK, Ocius KL, Apostolos AJ, Pires MM, Bishai WR, et al. A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice. eLife. 2024;13. doi:10.7554/elife.89157
BibTeX
@article{Shaku2024,
author = {Shaku, Moagi Tube and Um, Peter K and Ocius, Karl L and Apostolos, Alexis J and Pires, Marcos M and Bishai, William R and Kana, Bavesh D},
title = {A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice},
journal = {eLife},
year = {2024},
volume = {13},
doi = {10.7554/elife.89157}
}
EUVIMED